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comes of repeated treatment with tegaserod compared to usual
care in a hypothetical cohort of 1000 female patients ages 18–65
years. Probability and utility estimates were obtained from clin-
ical trials; costs were derived from published fee schedules and
other sources. Using a societal perspective over a 60-week time
horizon, treatment of tegaserod was compared to usual care
based on costs, quality-adjusted life-years (QALYs), and incre-
mental cost-utility ratio (ICUR). One-way sensitivity analyses
were conducted to assess the effect of varying baseline estimates
within plausible ranges on ICUR, and a probabilistic sensitivity
analysis in which parameters were varied simultaneously over
predeﬁned probability distributions was conducted. RESULTS:
Although the cost of tegaserod treatment was higher than 
that of usual care ($1,070,761 vs. $173,000), the outcomes of
tegaserod treatment were also better than those of usual care
(834 QALYs vs. 806 QALYs). The resulting incremental cost-
utility ratio was $32,113/QALY. The probability that tegaserod
remains cost-effective within the generally accepted $50,000 per
QALY decision threshold is more than 80%. One-way sensitiv-
ity analyses demonstrate that the results are most sensitive to the
costs of tegaserod and the utilities associated with treated and
untreated IBS. In probabilistic sensitivity analyses, the costs of
tegaserod accounted for 77% of variation in the ICUR. CON-
CLUSIONS: For treatment of IBS-C in females, tegaserod is cost-
effective compared to usual care.
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OBJECTIVES: The Brazilian government has published guid-
ance for the use of peguilated interferons for the treatment of
CHC in adults. However, there is no differentiation between the
drugs either concerning efﬁcacy or cost effectiveness. We used a
previously published Brazilian Markov model to compare these
two drugs in terms of cost utility. METHODS: The Brazilian
Markov model describes the clinical history of CHC in which
cohorts of hepatitis C virus (HCV) patients receive peginterferon
alfa 2b or peginterferon alfa 2a for either 48 or 24 weeks accord-
ing to genotype and liver histology and were followed for their
life expected life time. The reference patient was a 30-year-old
male with CHC without cirrhosis. The SVRs to PEG2b and
PEG2a were 48% and 46% for HCV genotype 1 and 88% and
76% for non-1, respectively. Quality of life for each health state
was based on literature. Costs for each health state was based
on three Delphi panels, one with hepatologists, one with inten-
sivists and another with oncologists. Costs in 2005 reais and ben-
eﬁts were discounted at 3%. RESULTS: In HCV genotype 1
PEG2b increases life expectancy (LY) by 0.07 years and quality
adjusted life expectancy (QALY) by 0.13 years compared to
PEG2a. In these patients PEG2b is less costly than PEG2a 
(R$3.763,33 difference). In HCV non-genotype 1 patients
PEG2b increases LY by 0.44 and QALY by 0.76. Also, in HCV
non-genotype 1 patients PEG2b was less costly than PEG2a 
(R$6.371,04 difference). CONCLUSIONS: Peguinterferon alfa
2b is dominant, in pharmacoeconomics terms, in comparison to
PEG2a for the treatment of HCV adult patients, in Brazil.
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OBJECTIVE: To determine cost-utility of the treatment alterna-
tives of C virus hepatitis (CVH) in the Mexican Institute of Social
Security (IMSS): a) Peginterferon, b) Peginterferon plus Rib-
avirin, c) Peginterferon plus Ribavirin plus Thymosin in those
patients that did not respond to interferon plus Ribavirin, and
d) and ﬁnally, not using any drug. METHODS: A cost-utility
analysis was performed using a decision tree and a Markov
model to simulate a cohort of 30-year-old male patients with
CVH without chronic complications. The follow-up was till their
death. The cost information was gotten from a Mexican expert
panel and effectiveness data were taken from a clinical trial in
Mexican population. The perspective used was institutional and
a 3% discount rate was applied for costs and effectiveness. Costs
were reported in 2005 US dollars. The sensitivity analysis per-
formed included one-way, two-way, threshold and probabilistic.
Acceptability curves and health net beneﬁts were estimated.
RESULTS: The most costly and least effective option was not
using any drug, with $4716 per QALY. The alternative with less
cost per QALY was the one that included Thymosin ($2246) fol-
lowed by Peginterferon plus Ribavirin ($2492) and Peginterferon
alone ($3229). CONCLUSIONS: The alternatives of not using
any drug and the one based on Peginterferon were dominated.
Triple therapy (Peginterferon plus Ribavirin plus Thymosin) was
the most expensive and effective. Therefore the decision about
using triple therapy and Peginterferon plus Ribavirin will depend
on willingness to pay.
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OBJECTIVE: To assess the effect of prior authorization (PA) on
the appropriate gastrointestinal (GI) prescribing of tegaserod in
a managed care population. METHODS: Retrospective analysis
was conducted of pharmacy and medical claims data of
tegaserod users from four geographically diverse managed care
health plans. Members who were continuously enrolled and ini-
tiated on tegaserod therapy between August 1, 2002 and Decem-
ber 31, 2003 were included in the study. The ﬁrst prescription
ﬁll date for tegaserod during this period was considered the index
prescription date. Index diagnosis visit was deﬁned as the closest
physician visit with a GI-related diagnosis either before or after
the index prescription date. Diagnostic characteristics were 
evaluated during a 2-year period (1 year before and 1 year after
the index prescription date). Appropriate GI prescribing of
tegaserod, deﬁned as a claim for IBS or at least one of its symp-
toms—abdominal pain, bloating, or constipation—was assessed
for plans with and without PA. RESULTS: In total, 2638
tegaserod users had an index diagnosis visit for a GI-related dis-
order; 93.5% were female, and the mean age was 48.6 (SD =
13.7) years. During the 24-month observation period, 93.6% of
the patients were appropriately prescribed tegaserod. Speciﬁcally,
they were diagnosed with IBS (56.4%), constipation (21.2%),
abdominal pain (15.8%), or bloating (1.3%). There were no dif-
